SCD & gene therapy: Who is it for?

Gene therapy, once a concept of science fiction, is now a reality, offering transformative treatments for certain illnesses by targeting the root cause: our genes. Genes act as the body's blueprint, dictating cell function. Errors in these instructions can lead to inherited diseases like Sickle Cell Disease (SCD), where a single gene mutation causes red blood cells to deform, leading to pain and organ damage.

“

Genes are the body’s instructions, its blueprint. They tell our cells how to grow, how to function and how to survive. But when just one instruction carries a mistake, the body suffers.

Unlike traditional treatments that only manage symptoms, gene therapy aims to correct the faulty gene itself. For conditions such as SCD, thalassaemia, spinal muscular atrophy, and some rare forms of blindness, this approach offers the unprecedented possibility of a cure. The process typically involves collecting a patient's stem cells, repairing the defective gene in a laboratory, sometimes using technologies like CRISPR, and then returning the corrected cells to the patient.

“

Traditional treatments, like hydroxyurea or regular blood transfusions, only manage symptoms. They cannot touch the faulty gene itself. Gene therapy, however, is different. It aims to correct the mistake at its source, giving the body a chance to produce healthy red blood cells again.

However, gene therapy is not a simple procedure. It is a lengthy and intensive process that may require chemotherapy, carrying significant risks including infertility, infection, and weakened immunity. Furthermore, the long-term effectiveness of the therapy remains uncertain for some patients, with results varying.

“

The cost is staggering, often more than a million pounds for one patient. It means that access is limited to wealthy countries and specialised hospitals.

The most significant barrier to gene therapy is its staggering cost, often exceeding one million pounds per patient. This financial hurdle restricts access primarily to wealthy countries and specialized medical centers. Ironically, SCD, the disease gene therapy could revolutionize, is most prevalent in sub-Saharan Africa, India, and the Caribbean, regions least equipped to afford or provide such advanced treatments. This creates a stark disparity, where a child in a developed nation might access this life-changing therapy, while a child in a region with a high prevalence of the disease may not.

“

SCD is most common in sub-Saharan Africa, India and parts of the Caribbean. Yet those very regions where the need is greatest are the least likely to benefit.